Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

ADMA Biologics Company Profile (NASDAQ:ADMA)

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.83 (110.80% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
DateFirmActionRatingPrice TargetActions
5/18/2015ZacksUpgradeHold -> Buy$9.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Maxim GroupBoost Price TargetBuy$18.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015ZacksReiterated RatingHold -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2015Maxim GroupSet Price TargetBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Maxim GroupSet Price TargetBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014OppenheimerInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2014Maxim GroupBoost Price TargetBuy$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2014Maxim GroupReiterated RatingPositive -> Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2013Maxim GroupInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2013Ladenburg ThalmannInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/24/2013 forward)